In partnership with

The Reset Series™
Vitae Weekly Reset — Issue #39
On Guidance Being Rewritten
Five pieces this week, and four of them come back to the same thing: medical guidance quietly changing underneath conversations most people are still having on old terms.
Sleep apnea has been treated the same way for decades — mechanically holding the airway open with a mask that a substantial number of people can’t tolerate. An oral drug targeting the neuromuscular cause instead has now completed two Phase 3 trials and is under FDA review. Migraine prevention got its first comprehensive US guideline update in fourteen years, and its most interesting conclusion is that no single drug wins. Cardiovascular, kidney and metabolic health have just been formally bound together in the first CKM clinical guideline, with staging recommended across the life course. And the COVID vaccine programme has changed so substantially since 2020 — in target, products, regulation and who it’s even offered to — that a view formed during the rollout is a view about something else entirely.
The fifth piece is more practical: flu and COVID eligibility have diverged sharply this autumn, and assuming one implies the other no longer works.
None of it is dramatic. All of it changes what the right answer looks like.
— The Vitae Team
Sleep apnea
 
This week on the Vitae blog
What Actually Happens When You Have Sleep Apnea
Sleep apnea repeatedly disrupts breathing while you sleep. Here’s what actually happens, how it’s treated, and why a new oral drug could change treatment.
Read →
 
The First New Migraine Guideline in 14 Years
A major new migraine guideline reviews 217 studies and updates when prevention should be offered, which treatments work and how long to try them.
Read →
 
What’s Actually Changed With the COVID Vaccine Since 2020
The COVID vaccine programme has changed substantially since 2020 — in target, regulation, products and, in the UK, who it’s actually for.
Read →
 
Flu and COVID Jabs: Why the Two Lists No Longer Match
Flu and COVID vaccine eligibility have diverged significantly this autumn. Here’s who qualifies for each, when to book, and why the lists are now so different.
Read →
 
Why Medicine Is Rethinking Heart, Kidney and Metabolic Health
Heart, kidney and metabolic health are increasingly being treated as one interconnected system. Here’s what CKM syndrome means and why medicine is changing.
Read →

One Pergola, Endless Ways to Fit Your Space

Relaxing patio, spacious backyard, or anything in between - there's a Hansø pergola built to fit it. Freestanding or wall-mounted, the right finish, sizes from 10'x10' up. Same precision engineering, every time.

Save now 35% on Horizon and Pro+ pergolas, plus a FREE ProCheck Care™ 10-Year Plan.

Find Your Pergola Now

This week’s deep dive
What’s Actually Changed With the COVID Vaccine
Ask most people what they think about the COVID vaccine and the answer is usually shaped by 2020 or 2021. Five years on, four separate things have changed — and only one of them gets much attention.
The target has changed repeatedly. The 2020 vaccines were designed against the ancestral SARS-CoV-2 spike protein, a version that stopped circulating meaningfully years ago. US vaccines have since moved through bivalent formulations, XBB.1.5, KP.2, LP.8.1 and now XFG for 2026–27. XFG-adapted Pfizer COMIRNATY is listed as currently available in the UK too, though UK and US authorisation remain separate processes.
The regulatory model has changed. Annual strain updates don’t restart development from Phase 1. Regulators draw on accumulated evidence for the established platform plus data specific to the updated formulation — manufacturing, quality, non-clinical and, where required, immunogenicity. It resembles the seasonal flu approach, though the frameworks aren’t identical.
The products have diversified. Moderna’s mNEXSPIKE encodes only two regions of the spike protein rather than the full-length version — a genuine design change, separately evaluated before approval. Novavax’s Nuvaxovid isn’t an mRNA vaccine at all.
And in Britain, the programme itself has changed. Autumn 2026 eligibility covers adults 75 and over, older-adult care home residents, and immunosuppressed people aged 6 months and over. That’s a targeted intervention, not the population-wide offer of 2021.
A major JAMA review published on 2 September found no new safety signals across 155 publications — while also being candid that only 3 of its 84 comparative observational studies were at low risk of bias, and that established concerns like myocarditis in younger males remain recognised in regulatory warnings.
None of that tells anyone what to do. It does mean a position formed five years ago was formed about a different vaccine, a different evidence base and a different programme.
Read the full piece →
 
Quick wins for this week
Check flu and COVID eligibility separately
They’re different lists now. A healthy 68-year-old qualifies for flu but not COVID. So does a pregnant woman, and a 45-year-old with diabetes.
Give a migraine preventive 8–12 weeks at the right dose
That’s the new guideline’s own standard for judging whether it works. Abandoning it at three weeks tells you nothing. OnabotulinumtoxinA needs 24 weeks.
If flu vaccination applies to you, aim for October into November
The vaccine takes about two weeks to reach full protection, and flu usually peaks in December or January.
Persistent daytime tiredness deserves a proper assessment, not a guess
Sleep apnea can’t be diagnosed from symptoms alone. If loud snoring, breathing pauses or morning headaches are in the picture, that’s a sleep study conversation.

Smart starts here.

You don't have to read everything — just the right thing. 1440's daily newsletter distills the day's biggest stories from 100+ sources into one quick, 5-minute read. It's the fastest way to stay sharp, sound informed, and actually understand what's happening in the world. Join 4.5 million readers who start their day the smart way.

Join for free today!

 
The Reset Companion
Working out whether a guideline change, an eligibility rule or a new treatment actually applies to your situation is exactly the kind of question the Reset Companion is built to help with.
Try the Reset Companion — 30 free messages →
 
There’s a pattern in all five pieces worth naming. Medical guidance changes quietly. The migraine guideline took fourteen years to update. The CKM framework went from a concept to a clinical guideline in three. The COVID programme narrowed so gradually that most people didn’t notice they’d stopped being eligible.
Meanwhile, the conversations around these things tend to stay fixed at whatever was true when someone last paid attention. That’s not anyone’s failing — nobody can track every guideline in every field. It’s just worth occasionally checking whether the thing you know is still the thing that’s true.
Back in two weeks.
The Vitae Team

This Isn't Just Another Patio Cover

There's always one backyard everyone talks about. This time, make it yours.

A Hansø pergola isn't the same flimsy patio cover - up to 167 mph wind rating, 65 PSF snow load, T6 aerospace-grade aluminum.

Save 35% on Horizon and Pro+, plus a FREE ProCheck Care™ 10-Year Plan.

Find Your Pergola Now

Keep reading

View more
caret-right
© 2026 Vitae: The Reset Series™.
beehiivPowered by beehiiv